Breaking News, Promotions & Moves

Evergreen Theragnostics Completes $15M Series B, Launches Discovery Unit

The company will use funds from the recent capital raise to prepare for the launch of Ga-68 DOTATOC.

Evergreen Theragnostics, a clinical stage contract development and manufacturing organization (CDMO) developing radiopharmaceuticals for cancer therapy, completed a $15 million Series B capital raise. Evergreen is also launching a new business unit, Evergreen Discovery, which is focused on developing novel radiopharmaceuticals for cancer therapy. To support its new business unit, Evergreen recruited Thomas Reiner as its chief scientific officer. Previously, Reiner served as head of Radiolig a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters